Join IAG’s Bio-Partnering at HC Wainwright 2020

Join IAG's Bio-Partnering at HC Wainwright 2020

Join IAG’s Venture Partners and Bio-Partnering Team at HC Wainwright 2020

Dr. Olga Kubassova, IAG’s CEO, and David Chia, IAG’s CCO and Head of Bio-Partnering will virtually attend HC Wainwright  biotech-investor meeting, 14-16 September 2020.

Together with our Venture Partners, IAG  is building a diversified investment portfolio of innovative life science companies at various stages of clinical development.

We co-develop, co-invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immuno-oncology, oncology, inflammation, rheumatology, musculoskeletal, immunology markets.

Our portfolio companies take full advantage of a wide range of IAG’s innovative R&D solutions, operational breadth and expertise, risk-sharing financing and partnership models.

More on our recent partnerships can be found here:

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:

Reach out:

Follow the Company: Linkedin